HAG
ALNY icon

HighPoint Advisor Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

HighPoint Advisor Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-832
Closed -$331K – 665
2025
Q4 		$331K Buy
832
+128
+18% +$56.6K 0.01% 809
2025
Q3 		$321K Buy
+704
New +$287K 0.02% 514

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighPoint Advisor Group's ALNY Position: Q1 2026 in Review

HighPoint Advisor Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 832 shares — an estimated $331K sold.

HighPoint Advisor Group first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $331K in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • HighPoint Advisor Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • HighPoint Advisor Group sold 832 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $331K.
  • HighPoint Advisor Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • HighPoint Advisor Group's Alnylam Pharmaceuticals position peaked at $331K in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on HighPoint Advisor Group's 13F filing for Q1 2026, filed 14 May 2026.